

Index

Drug Master File (MF).....	5		
	1		
15-Day reports.....	36		
	7		
7-Day reports.....	36		
	A		
ADR reporting system.....	95		
Age classification for pediatric use.....	90		
AIDS Research Center (NIID).....	6		
APPROVAL AND LICENSES			
Acceptance of foreign clinical trial data	43		
Application forms	14		
Data required for approval applications.....	41		
Data to be Attached to Approval Application	41		
Approval and Licenses			
Approval Applications for Drugs Manufactured in Foreign Countries	4		
Approval And Licenses			
Drug Manufacturing/Marketing Approvals.....	34		
Approval And Licenses			
Approval Review.....	34		
Article 42 of the Pharmaceutical Affairs Law.....	25		
	B		
Biosimilar Products	23		
Biotechnological products.....	44		
Blood and Blood Products Division (PFSB).....	44		
Brand Names of Prescriptions Drugs.....	93		
bridging studies.....	42		
	C		
Clinical Studies	42		
Clinical study reports	42		
Combination Products	22		
Commentaries on Precautions in package inserts.....	97		
Compliance and Narcotics Division (PFSB).....	1		
COMPLIANCE SURVEYS			
STATUS FOR FOR REEXAMINATION BASED ON GPSP	15		
Common Technical Document (CTD)	21		
	D		
DEVELOPMENT OF NEW DRUGS	35		
Dissemination of drug information			
SAFETY INFORMATION	90		
Dissemination of information	4		
Drug Abuse Control	19		
DRUG PRICING SYSTEM	102		
Drug Safety Update	97		
Drugs			
Classification	63		
Quality Standards and Government Certification	16		
Quality Standards Based on Notifications	26		
Drugs for Pediatric Use.....	22		
	E		
Economic Affairs Division (HPB).....	3		
ELECTRONIC INFORMATION DISSEMINATION.....	97		
Emergency safety information	94		
ENTRY OF GENERIC DRUGS	105		
	F, G		
General Affairs Division (PFSB)	1		
Global harmonization of GMP			
Mutual approvals of GMP	40		
GMP			
Compliance review			
GMP			
Compliance review	20		
Global harmonization			
GMP			
Mutual approvals	20		
Investigational products GMP			
Investigational products	34		
Standards to assure quality of imported drugs (GMPI)			
GMP			
Standards to assure quality of imported drugs (GMPI)	53		
GMPI			
Standards to assure quality			
GMPI			
Standards to assure quality	53		
Good Clinical Practice (GCP).....	4		
Good Laboratory Practice (GLP).....	4		
Good Manufacturing Practice (GMP)			
→Necessity.....	93		
Good Post-marketing Study Practice (GPMSPP).....	17		
Good Vigilance Practice (GVP).....	→ GVP		
Government Batch Test			
Quality Of Drugs	4		
GPMSPP	17		
GPSP			
COMPLIANCE STATUS FOR REEXAMINATION.....	83		
GPSP	17		
Guidance-mandatory drugs.....	12		
Guidelines			
Clinical evaluation.....	45		
Specifications of drugs:Guidelines: Specifications of drugs	92		
Guidelines for bioequivalence Studies	47		
Guidelines for General Pharmacological Studies.....	47		
Guidelines for Pharmacokinetic Studies.....	47		
Guidelines for Stability Tests	44		
Guidelines for Toxicity Tests.....	45		
	H		
Health and Medical Services Law for the Aged.....	102		
Health insurance programs	102		
HISTORY	102		
HEALTH POLICY BUREAU (HPB).....	1		
HISTORY OF HEALTH INSURANCE PROGRAMS.....	102		
	I		
ICH130			
IF			
Pharmaceutical Interview Forms.....	194		
Information for drugs which completed reexamination or reevaluation	97		
International Conference on Harmonization (ICH)			
International Conference on Harmonization (ICH)	21		
	J		
Japanese Pharmacopoeia (JP).....	4		
	L		
Labeling and Package Inserts			
Necessity	16		
Labeling of excipients.....	93		
Law Concerning Access to Information.....	18		

Participating Company List

Under the supervision of Ministry of Health Labour and Welfare Japan, this publication has been updated regularly with the cooperation of the enthusiastic editors below.

Leader: Katsunori KURUSU

(Chapter 1)	Sanofi KK	Regulatory Affairs: Katsunori KURUSU
(Chapter 2)	Eisai Co, Ltd	Japan Development Regulatory Affairs Global Regulatory Affairs CFU: Tsuyoshi KOBAYASHI
	Takeda Pharmaceutical Company Limited	Regulatory Affairs: Katsunori INUI
(Chapter 3)	Daiichi Sankyo Co, Ltd	New Drug Regulatory Affairs: Yoshiyuki HATTORI
	Janssen Pharmaceutical KK	Regulatory Development Department : Kazuhiro SASAKI
	MSD KK	Regulatory Strategy & Liaison 3: Jun ISHIHARA Regulatory Policy & Intelligence : Kanji Hirai
	UCB Japan Co, Ltd	Regulatory Affairs: Yasuhiro HASEGAWA
(Chapter 4)	Shionogi & Co, Ltd	Regulatory Strategy Global Regulatory Affairs: Kazuyo MARUCHI
	Kyowa Hakko Kirin Co, Ltd	Pharmacovigilance and Quality Assurance: Hiroyuki OHTSUKA
(Chapter 5)	Chugai Pharmaceutical Co, Ltd	Quality & Regulatory Compliance: Yuichi TAKIDO
(Chapter 6)	Otsuka Pharmaceutical Co, Ltd	Regulatory Affairs Department: Toshio SATO

Contact:

Administrative Office	JAPAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION	Office of International Affairs
	2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023, Japan e-Mail address: international @ jpma.or.jp Phone 81-3 (3241) 0326 Fax 81-3 (3242) 1767	

PHARMACEUTICAL ADMINISTRATION AND REGULATIONS IN JAPAN

Edited by **Regulatory Information Task Force**
International Affairs Committee

July 31, 2015

© **JAPAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION**

2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023, Japan

Phone 81-3 (3241) 0326 Fax 81-3 (3242) 1767

<http://www.jpma.or.jp/12english/index.html>